CKAP2L Promotes Proliferation and Migration of Glioma Cells in a DIAPH3-Deficient Model
Cells · 31.10.2026 · 15 (21) · 1996
DOI: 10.3390/cells15211996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 31.10.2026. Verfasst von Asma Mahdi und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Health and Life Sciences, Hamad Bin Khalifa University, Penrose House Building, Education City, Doha P.O. Box 34110, Qatar. Hauptthemen laut MEDLINE: Cell Movement, Glioma, Formins, Brain Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Research Fund, Stichting tegen Kanker, Hamad bin Khalifa University.
Abstract (Originalsprache)
In humans, low expression of DIAPH3 is associated with poor prognosis in glioblastoma patients. In mice, DIAPH3 loss induces aberrant mitosis, chromosomal instability, and cell death; whereas the combined loss of DIAPH3 and p53 causes high-grade diffuse glioma and accelerates tumor onset. In this study, we used Diaph3/p53 double conditional knockout mice (dcKO) and ultra-high-resolution MRI to detect and characterize the development and progression of glioma. We transcriptionally profiled early and advanced gliomas and identified stage-dependent alterations in molecular signatures as the tumor progresses. Notably, genetic pathways underlying self-renewal and extracellular matrix (ECM) interactions were upregulated at the expense of neural activity signature, which was severely shrunk. CKAP2L was identified as a differentially expressed gene at both early and advanced tumor stages in the dcKO mice. A subsequent siRNA screen to identify genes involved in proliferation and migration of glioblastoma cells identified CKAP2L as a top hit. Functional studies showed that CKAP2L depletion reduced proliferation and migration and induced cell accumulation in G2/M phase of the cell cycle. We also used data mining and thoroughly characterized the relationship between CKAP2L expression and glioma development. We found that CKAP2L expression correlates with proliferative and progenitor-associated markers, pointing to a potential role in maintaining highly proliferative and progenitor-like tumor cell state. We also identified a differentially methylated CpG site in the CKAP2L promoter that was associated with changes in gene expression across glioma datasets. Overall, our findings show that CKAP2L may contribute to glioma progression, help distinguish tumor grade, and represent a potential therapeutic target in glioblastoma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Health and Life Sciences, Hamad Bin Khalifa University, Penrose House Building, Education City, Doha P.O. Box 34110, Qatar.
- Developmental Neurobiology Laboratory, Institute of Neuroscience, Université Catholique de Louvain, 1200 Brussels, Belgium.
ORCID-Profile: Hend Salah Fayed, Mohamed Aittaleb, Maisa Ismael Alkailani, Fadel Tissir
Förderung
- Qatar National Research Fund
- Stichting tegen Kanker
- Hamad bin Khalifa University
Zitieren
APA
Mahdi, A., Aldaalis, A., Chehade, G., Lau, E. O., Fayed, H. S., Zen, A. A. H., Aittaleb, M., Alkailani, M. I., & Tissir, F. (2026). CKAP2L Promotes Proliferation and Migration of Glioma Cells in a DIAPH3-Deficient Model. Cells, 15(21), 1996. https://doi.org/10.3390/cells15211996
Vancouver
Mahdi A, Aldaalis A, Chehade G, Lau EO, Fayed HS, Zen AAH, et al. CKAP2L Promotes Proliferation and Migration of Glioma Cells in a DIAPH3-Deficient Model. Cells. 2026;15(21):1996. doi:10.3390/cells15211996
BibTeX
@article{Mahdi2026,
author = {Mahdi, Asma and Aldaalis, Arwa and Chehade, Georges and Lau, Eva On-Chai and Fayed, Hend Salah and Zen, Ayman Al Haj and Aittaleb, Mohamed and Alkailani, Maisa Ismael and Tissir, Fadel},
title = {CKAP2L Promotes Proliferation and Migration of Glioma Cells in a DIAPH3-Deficient Model},
journal = {Cells},
year = {2026},
volume = {15},
number = {21},
pages = {1996},
doi = {10.3390/cells15211996}
}
EUVIMED